Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 55-61

  Chang, Shih Chieh ^a   Chang, Cheng Yu ^b   Chang, Shu Ju ^c   Yuan, Mei Kang ^a   Lai, Yi Chun ^a   Liu, Yu Chang ^a   Chen, Cheng Yu ^a   Kuo, Li Chiao ^a   Yu, Chong Jen ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c ALETHEIA UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Gefitinib; Incidence; Interstitial lung disease; Non small cell lung cancer; Outcome

Indexed keywords

CORTICOSTEROID; GEFITINIB; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; COUGHING; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MORTALITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME;

AGED; ANOXIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COUGH; DYSPNEA; FEMALE; HOSPITAL MORTALITY; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84871553618     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.03.009     Document Type: Article

References (31)

1. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
2. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
3. A. Inoue, Y. Saijo, M. Maemondo Severe acute interstitial pneumonia and gefitinib Lancet 361 2003 137 139
4. S. Kudoh, H. Kato, Y. Nishiwaki Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study Am J Respir Crit Care Med 177 2008 1348 1357
5. A. Armour Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin Asia Pac J Clin Oncol 3 2007 66 78
6. Y.N. Shih, C.H. Chiu, C.M. Tsai Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer J Chin Med Assoc 68 2005 183 186
7. K. Kataoka, H. Taniguchi, Y. Hasegawa Interstitial lung disease associated with gefitinib Respir Med 100 2006 698 704
8. M. Endo, T. Johkoh, K. Kimura Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group Lung Cancer 52 2006 135 140
9. M. Ando, I. Okamoto, N. Yamamoto Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 24 2006 2549 2556
10. M.M. Oken, R.H. Creech, D.C. Tormey Toxicity and response criteria of the eastern cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
11. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. M.H. Cohen, G.A. Williams, R. Sridhara FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 8 2003 303 306
14. A. Yoshimoto, K. Kasahara, H. Kimura Transient liver injury caused by gefitinib [in Japanese] Nihon Kokyuki Gakkai Zasshi 42 2004 56 61
15. C. Ho, J. Davis, F. Anderson Side effects related to cancer treatment: CASE 1 Hepatitis following treatment with gefitinib J Clin Oncol 23 2005 8531 8533
16. N.P. van Erp, H. Gelderblom, H.J. Guchelaar Clinical pharmacokinetics of tyrosine kinase inhibitors Cancer Treat Rev 35 2009 692 706
17. C.H. Yang, C.J. Yu, J.Y. Shih Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy J Clin Oncol 26 2008 2745 2753
18. S.C. Chang, C.Y. Chang, C.Y. Chen Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia J Thorac Oncol 5 2010 1105 1106
19. V. Liu, D.A. White, M.F. Zakowski Pulmonary toxicity associated with erlotinib Chest 132 2007 1042 1044
20. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
21. R.P. Perng, C.H. Yang, Y.M. Chen High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy Lung Cancer 62 2008 78 84
22. T. Fukui, S. Otani, R. Hataishi Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease Cancer Chemother Pharmacol 65 2010 803 806
23. M. Takeda, I. Okamoto, C. Makimura Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease J Thorac Oncol 5 2010 1103 1104
24. J.Y. Wu, J.Y. Shih, C.H. Yang Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer Int J Cancer 126 2010 247 255
25. H. Suzuki, K. Aoshiba, N. Yokohori Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis Cancer Res 63 2003 5054 5059
26. J.B. Hoag, A. Azizi, T.J. Doherty Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review J Exp Clin Cancer Res 28 2009 113
27. J.Y. Wu, C.J. Yu, C.H. Yang First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Am J Respir Crit Care Med 178 2008 847 853
28. M.K. Yuan, C.Y. Chang, S.C. Chang Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease Int J Clin Pharmacol Ther 49 2011 587 593
29. T. Seto, N. Seki, K. Uematsu Gefitinib-induced lung injury successfully treated with high-dose corticosteroids Respirology 11 2006 113 116
30. K. Hotta, K. Kiura, N. Takigawa Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience J Thorac Oncol 5 2010 179 184
31. S. Inomata, H. Takahashi, M. Nagata Acute lung injury as an adverse event of gefitinib Anticancer Drugs 15 2004 461 467